Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Tvardi Therapeutics (TVRD) Revenue (2016 - 2025)

Tvardi Therapeutics' Revenue history spans 13 years, with the latest figure at $2.6 million for Q1 2025.

  • On a quarterly basis, Revenue rose 20.33% to $2.6 million in Q1 2025 year-over-year; TTM through Mar 2025 was $7.6 million, a 55.3% decrease, with the full-year FY2024 number at $7.1 million, down 65.96% from a year prior.
  • Revenue hit $2.6 million in Q1 2025 for Tvardi Therapeutics, up from $1.5 million in the prior quarter.
  • Over the last five years, Revenue for TVRD hit a ceiling of $23.0 million in Q2 2022 and a floor of $821000.0 in Q4 2021.
  • Historically, Revenue has averaged $6.0 million across 5 years, with a median of $3.1 million in 2022.
  • Biggest five-year swings in Revenue: crashed 99.26% in 2021 and later skyrocketed 297.2% in 2022.
  • Tracing TVRD's Revenue over 5 years: stood at $821000.0 in 2021, then skyrocketed by 297.2% to $3.3 million in 2022, then dropped by 7.88% to $3.0 million in 2023, then plummeted by 51.56% to $1.5 million in 2024, then soared by 76.56% to $2.6 million in 2025.
  • Business Quant data shows Revenue for TVRD at $2.6 million in Q1 2025, $1.5 million in Q4 2024, and $2.6 million in Q3 2024.